Global Total Intravenous Anesthesia (TIVA) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Total Intravenous Anesthesia (TIVA) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Total intravenous anesthesia (TIVA) can be defined as a general anesthesia technique using only a combination of drugs given by the intravenous route, without the use of inhalants (gas anesthesia). The most commonly used drug is propofol. TIVA can be achieved as a single drug to shorten surgery time or in combination with other drugs. The drug combination to achieve TIVA will depend on many factors and should be considered based on the individual needs of the patient, including surgical requirements and planned surgical procedures that reflect the individual needs of the patient. Total intravenous anesthesia (TIVA) has become a popular and practical choice of anesthesia.

Market Overview:

The latest research study on the global Total Intravenous Anesthesia (TIVA) market finds that the global Total Intravenous Anesthesia (TIVA) market reached a value of USD 2066.91 million in 2022. It’s expected that the market will achieve USD 2934.93 million by 2028, exhibiting a CAGR of 6.02% during the forecast period.

Total Intravenous Anesthesia (TIVA) Market Drivers

TIVA is used to induce general anesthesia while avoiding the disadvantages of volatile anesthesia (and traditional inhalants). Intravenous anesthetic titrated at safe doses to maintain anesthesia for stage III surgery (loss of consciousness, amnesia, immobility and unresponsiveness to noxious stimuli). The use of TIVA is advantageous in situations where volatile anesthesia is high risk or not possible, as in some cases involving morbidly obese patients. TIVA is also used for anesthesia at traumatic sites such as severe accidents, disasters and wars.

Advances in medical technology and advances in medical equipment have allowed TIVA to be not only maintained by an IV set, but also assisted by electroencephalogram (EEG) monitoring. Propofol-based TIVA significantly improves postoperative recovery and comfort, minimizes nausea and vomiting, promotes rapid recovery, improves hemodynamic stability, preserves hypoxic pulmonary vasoconstriction, reduces intracerebral pressure, and Reduced risk of organ toxicity. Many patients prefer total intravenous anesthesia considering the comfort and safety of anesthesia and postoperative recovery.

A variety of infusion devices have improved the clinical practicability of TIVA, and high-quality infusion devices are conducive to the stable exertion of drug efficacy

Delivery of intravenous anesthetics depends on different types of infusion sets. Examples of infusion devices include smart pumps, syringe pumps, and goal-controlled infusion (TCI) devices.

First of all, smart pumps are suitable for patients who are bedridden, hospitalized, and intravenously injected for a long time. Smart pumps are commonly used to administer strong anesthetics and various vasoactive drugs, such as vasopressors, inotropes, and vasodilators, which require continuous titration in the operating room. Smart pumps are advantageous because they administer safe doses at programmed infusion rates within pre-existing constraints based on institutional standardized drug libraries. High-quality equipment is conducive to better efficacy of total intravenous anesthesia, and hospitals can provide better medical services for suitable groups of people.

Syringe pumps are smaller infusion pumps that allow small amounts of inducer to be administered at precise rates. Syringe pump accuracy depends on the syringe selected during pump programming. Most pumps will automatically recognize the syringe size when the syringe manufacturer's name is entered correctly. Syringes are generally simpler and quicker to use.

Target Controlled Infusion (TCI) systems are aided by computerized systems that utilize pharmacokinetic and pharmacodynamic models to maintain target concentrations of anesthetics in the brain. TCI requires the clinician to enter a target concentration of an anesthetic or other agent, a computer calculates the amount of drug required to enter the concentration, and an infusion pump is used to deliver the calculated bolus dose. The computer then constantly recalculates how much drug is in the system and affects the amount of drug needed to maintain the desired concentration at the site of action.

With the continuous development of the pharmaceutical industry towards intelligence and digitalization, TIVA's dose control is more precise, and the monitoring and drug control of each stage during anesthesia have reached the best state. The innovation and follow-up of infusion equipment is conducive to enhancing the performance and safety of products and improving the comfort of patients. Furthermore, for hospitals, the use efficiency and effect of TIVA-related devices can improve the cost performance of purchasing equipment.

Region Overview:

In 2022, the share of the Total Intravenous Anesthesia (TIVA) market in Asia Pacific stood at 33.37%.

Company Overview:

Fresenius-Kabi, Aspen Pharmacare, Nhwa were the top 3 players in the Total Intravenous Anesthesia (TIVA) market in 2022, taking up a market share of 32.27% together.

Fresenius Kabi is a global healthcare company specializing in life-saving medicines and technologies in infusion, blood transfusion and clinical nutrition. The company's products and services are used in the treatment and care of critically ill and chronically ill patients.

Its product portfolio includes a portfolio of highly complex biopharmaceuticals, clinical nutrition, medtech and IV generics. In biopharmaceuticals, Fresenius Kabi offers biosimilars focused on autoimmune diseases and oncology, among others. The company's clinical nutrition offerings include a broad range of enteral and parenteral nutrition products. In the field of medical technology, its products include important disposables, infusion pumps, apheresis machines, cell therapy equipment and more.
With Caring for Life as its corporate mission, Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and find the best answers to the challenges they face.

Aspen Pharmacare Holdings Limited is a listed multinational pharmaceutical company headquartered in Umhlanga, South Africa. Established in 1997, it listed on the Johannesburg Stock Exchange (JSE) in 1998 and acquired South African Druggists in 1999 before expanding internationally. Aspen is currently the largest pharmaceutical company in Africa through aggressive consolidation and expansion, with major manufacturing bases in places such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss in the Netherlands.

Aspen is known for manufacturing and distributing brand-name drugs as well as generic HIV/AIDS antiretrovirals (ARVs) and cancer drugs. Among other products, Aspen is also involved in the production of Janssen's COVID-19 vaccine through fill and finish,and has the right to market the product under its own brand name, Aspenovax.

Segmentation Overview:

By type,Propofol segment accounted for the largest share of market in 2022.

Propofol

Propofol is often the sedative drug of choice for the maintenance of general anesthesia via TIVA because of its rapid onset of action, rapid wear-off, beneficial properties, and few adverse effects. Propofol currently occupies the largest market share of TIVA drugs and is the most widely used.

Etomidate

Etomidate is also a commonly used TIVA drug in clinical practice, and it is mainly used for general anesthesia induction and anesthesia assistance. Among intravenous anesthetics, etomidate has the highest cardiovascular and respiratory safety and is suitable for most patients, especially elderly patients, and patients with poor cardiovascular function.

Application Overview:

The market's largest segment by application is the segment Heart Surgery, with a market share of 24.13% in 2022.

Key Companies in the global Total Intravenous Anesthesia (TIVA) market covered in Chapter 3:

Fresenius-Kabi
Xian Libang Pharmaceutical
Par Pharmaceutical
Eugia US
Viatris
Nhwa
Pfizer Inc.
Aspen Pharmacare
Hikma Pharmaceuticals
Maruishi
Sagent Pharmaceuticals
B. Braun Medical

In Chapter 4 and Chapter 14.2, on the basis of types, the Total Intravenous Anesthesia (TIVA) market from 2018 to 2029 is primarily split into:

Propofol
Etomidate
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Total Intravenous Anesthesia (TIVA) market from 2018 to 2029 covers:

Cancer Surgery
Heart Surgery
Orthopedic Surgery
Cosmetic Surgery
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)